Charlie Johnson

Charlie Johnson brings over 20 years experience in strategic development, commercialization and management of service businesses within the oncology sector. With a notable track record in the ADC segment going back to 2004 when he established Avecia’s ADC manufacturing operations when the segment was in its infancy. Prior to joining ADC Biotechnology as Chief Executive in early 2012, Johnson held positions as Director for the High Potency Division of Dishman group’s Carbogen Amcis operation, headquartered in Basel and as Business Manager for the strategic marketing of the oncology portfolio of Italy’s UQUIFA. He previously held a series of pharma-related roles with ICI and AstraZeneca.